Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

Aptose Biosciences (APTO) announced that the Cohort Safety Review Committee – CSRC – monitoring Aptose’s Phase 1/2 TUSCANY trial of tuspetinib ...

Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

THE Technological University of the Shannon (TUS) has secured €2.4 million in funding through the latest Capital Equipment ...

Only six per cent of research in sport and exercise science globally focuses on women and girls, presenting a significant ...

An open evening is taking place in the Technological University of the Shannon (TUS) in Athlone today Wednesday, February 12, ...

A TUS Athlone student and social media lover has put her skills to good use by creating Content and Coffee afternoon to ...